Pour conclure, l’ensemble de nos résultats suggère que l’aptitude aérobie en altitude
est déterminée par le transport d’O2. Celui-ci peut être augmenté par manipulation
pharmacologique du débit ventriculaire droit maximal lors d’une inhibition de la VPH (sous
bosentan), par amélioration de l’oxémie (sous acétazolamide) ou par les deux conjointement
(sous sildénafil).
CHAPITRE VI: Biobliographie
1. Aldashev AA, Kojonazarov BK, Amatov TA, Sooronbaev TM, Mirrakhimov MM, Morrell NW, Wharton
J, Wilkins MR. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax. 2005; 60:
683-687.
2. Alexander JK, Grover RF. Mechanism of reduced cardiac stroke volume at high altitude. Clin. Cardiol.
1983; 6: 301-303.
3. Anand IS, Prasad BA, Chugh SS, Rao KR, Cornfield DN, Milla CE, Singh N, Singh S, Selvamurthy W.
Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema. Circulation. 1998; 98: 2441-5.
4. Anand IS, Wu T. Syndromes of subacute moutain sickness. High Alt. Med. Biol. 2004; 5(2): 156-170.
5. Alleman Y, Rotter M, Hutter D, Lipp E, Sartori C, Scherrer U, Seiler C. Impact of acute hypoxic
pulmonary hypertension on LV diastolic function in healthy mountaineers at high altitude. Am. J. Physiol.
Heart Circ. Physiol. 2004; 286: H856-H862.
6. Allen DG, Orchard CH. Myocardial contractile function during ischema and hypoxia. Circ. Res. 1987;
60: 153-168.
7. Andersen P, Saltin B. Maximal perfusion of skeletal muscle in man. J. Physiol. 1985; 366: 233-249.
8. Astrand PO, Astrand I. Heart rate during muscular work in man exposed to prolonged hypoxia. J. Appl.
Physiol. 1958; 13: 75-80.
9. Babcock M, Pegelow D, McClaran S, Suman O, Dempsey J. Contribution of diaphragmatic power output
to exercise-induced diaphragm fatigue. J. Appl. Physiol. 1995; 78: 1084-90.
10. Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003; 361: 1967-74.
11. Bärtsch P, Gibbs SR. Effect of altitude on the heart and the lungs. Circulation. 2007; 116: 2191-2202.
12. Bärtsch P, Mairbäurl H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary
edema. J. Appl. Physiol. 2005; 98: 1101-1110.
13. Bauer A, Demetz F, Bruegger D, Schmoelz M, Schroepfer S, Martignoni A, Baschnegger H, Hoelzl J,
Thiel M, Choukér A, Peter K, Gamble J, Christ F. Effect of high altitude and exercise on microvascular
parameters in acclimatized subjects. Clin. Sci. 2006; 110(2): 207-15.
14. Beall CM, Laskowski D, Strohl KP, et coll. Pulmonary nitric oxide in mountain dwellers. Nature. 2001;
414: 411-2.
15. Bebout DE, Story D, Roca J, Hogan MC, Poole DC, Gonzales-Camarena R, Ueno O, Haab P, Wagner
PD. Effects of altitude acclimatization on pulmonary gas exchange during exercise. J. Appl. Physiol. 1989;
67: 2286-2295.
16. Bender PR, Groves BM, McCullough RE, McCullough RG, Huang SY, Hamilton AJ, Wagner PD,
Cymerman A, Reeves JT. Oxygen transport to exercing leg in chronic hypoxia. J. Appl. Physiol. 1988; 65:
2592-97.
17. Berg JT, Ramanatha S, and Swenson ER. Inhibitors of hypoxic pulmonary vasoconstriction prevent
high-altitude pulmonary edema in rats. Wild Environ. Med. 2004; 15: 32-1537.
18. Berger MM, Dehnert C, Bailey D, Luks AM, Menold E, Castell C, Schendler G, Faoro V, Mairbäurl H,
Bärtsch P, Swenson ER. Transpulmonary exchange of endothelin-1 and nitrite in high-altitude pulmonary
artery hypertension.
19. Bernardi L, Schneider A, Pomidori L, Paolucci E, Cogo A. Hypoxic ventilatory response in successful
extreme altitude climbers. Eur. Respir. J. 2006; 27(1): 165-71.
20. Bigland-Ritchie B, Vollestad NK. Hypoxia and fatigue: How are they related? In: Sutton JR, Houston
CS, Coates G, eds. Hypoxia. The Tolerable limits. Indianapolis: Benchmark Press, 1988: 315-28.
21. Bland J, Altman D. Measuring agreement in method comparison studies. Stat. Methods Med. Res. 1999;
8: 135-160.
22. Blitzer ML, Loh E, Roddy MA, Stamler JS, Creager MA. Endothelium-derived nitric oxide regulates
systemic and pulmonary vascular resistance during acute hypoxia in humans. J. Am. Coll. Cardiol. 1996; 28:
591-596.
23. Bogaard HJ, Hopkins SR, Yamaya Y, Niizeki K, Ziegler MG, Wagner PD. Role of the autonomic
nervous system in the reduced maximal cardiac output at altitude. J. Appl. Physiol. 2002; 93(1): 271-9.
24. Boushel R, Calbet JA, Radegran G, Sondergaard H, Wagner PD, Saltin B. Parasympathetic neural
activity accounts for the lowering of exercise heart rate at high altitude. Circulation. 2001; 104: 1785-1791.
25. Boussuges A, Molenat F, Burnet H, Cauchy E, Gardette B, Sainty JM, Jammes Y, Richalet JP.
Operation Everest III : Modification of cardiac function secondary to altitude-induced hypoxia: an
echocardiographic and Doppler study. Am. J. Resp. Crit. Care Med. 2000; 161: 264-270.
26. Bradwell AR, Dykes PW, Coote JH, Forster PJ, Milles JJ, Chesner I, and Richardson NV. Effect of
acetazolamide on exercise performance and muscle mass at high altitude. Lancet. 1986; I: 1001–1005.
27. Brechue WF, and Stager JM. Acetazolamide alters temperature regulation during submaximal exercise.
J. Appl. Physiol. 1990; 69: 1402-1407.
28. Brimioulle S, LeJeune P, Naeije R. Effects of hypoxic pulmonary vasoconstriction on pulmonary gas
exchange. J. Appl. Physiol. 1996; 81(4): 1535-43.
29. Brooks GA, Butterfield GE, Wolfe RR, Groves BM, Mazzeo RS, Sutton JR, Wolfel EE, Reeves JT.
Decreased reliance on lactate during exercise after acclimatization to 4,300 m. J. Appl. Physiol. 1991; 71:
333-341,
30. Brutsaert TD, Parra EJ, Shriver MD, Gamboa A, Palacios JA, Rivera M, Rodriguez I, León-Velarde F.
Spanish genetic admixture is associated with larger V(O2) max decrement from sea level to 4338 m in
Peruvian Quechua. J. Appl. Physiol. 2003; 95(2): 519-28.
31. Busch T, Bärtsch P, Pappert D, Grunig E, Hildebrandt W, Elser H, Falke KJ, Swenson ER. Hypoxia
decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am. J. Respir.
Crit. Care Med. 2001; 163: 368-73.
32. Calbet JA, Boushel R, Radegran G, Sondergaard H, Wagner PD, Saltin B. Determinants of maximal
oxygen uptake in severe acute hypoxia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 284: R291-303.
33. Calbet JA, Boushel R, Radegran G, Sondergaard H, Wagner PD, Saltin B. Why is VO2 max after
altitude acclimatization still reduced despite normalization of arterial O2 content? Am. J. Physiol. Regul.
Integr. Comp. Physiol. 2003; 284: R304-316
34. Calbet JA, Rådegran G, Boushel R, Søndergaard H, Saltin B, Wagner PD. Effect of blood haemoglobin
concentration on VO2max and cardiovascular function in lowlanders acclimatised to 5260m. J. Physiol.
2002; 545, 715-728.
35. Calbet JA, Rådegran G, Boushel R, Søndergaard H, Saltin B, Wagner PD. Plasma volume expansion
does not increase maximal cardiac output or VO2 max in lowlanders acclimatized to altitude. Am. J.
Physiol. Heart Circ. Physiol. 2004; 287(3): H1214-24.
36. Cerretelli P. Limiting factors to oxygen transport on Mount Everest. J. Appl. Physiol. 1976; 40: 658-67.
37. Cerretelli P, Samaja M. Acide-base balance at exercise in normoxia and in chronic hypoxia. Revisiting
the “lactate paradox”. Eur. J. Appl. Physiol. 2003; 390 : 431-448.
38. Chen QH, Ri-Li Ge, Wang XZ, Chen HX, Wu TY, Kobayashi T, Yoshimura K. Exercise performance
of Tibetan and Han adolescents at altitude of 3417m and 4300m. J. Appl. Physiol. 1997; 83: 661-667.
39. Cibella F, Cuttitta G, Romano S, Grassi B, Bonsignore G, Milic-Emili J. Respiratory energetics during
exercise at high altitude. J. Appl. Physiol. 1999; 86: 1785-92.
40. Curtis SE, Walker TA, Bradley WE, Cain SM. Raising P50 increases tissue PO2 in canine skeletal
muscle but does not affect criticial O2 extraction ratio. J. Appl. Physiol. 1997; 83: 1681-1689.
41. Cymerman A, Reeves JT, Sutton JR, Rock PB, Groves BM, Malconian MK, Young PM, Wagner PD
and Houston CS. Opertaion Everest II: maximal oxygen uptake at extreme altitude. J. Appl. Physiol. 1989;
66: 2446-53.
42. Dantzker DR. The influence of cardiovascular function on gas exchange. Clin. Chest Med. 1983; 4:
149-159.
43. Dávila-Román VG, Guest TM, Tuteur PG, Rowe WJ, Ladenson JH, Jaffe AS. Transient right but not left
ventricular dysfunction after strenuous exercise at high altitude. J. Am. Coll. Cardiol. 1997; 30: 468-473.
44. Deboeck G, Niset G, Lamotte M, Vachiéry JL, Naeije R.. Exercise testing in pulmonary arterial
hypertension and in chronic heart failure. Eur. Respir. J. 2004; 23: 747-51.
45. Deem S, Hedges RG, Kerr ME, Swenson ER. Acetazolamide reduces hypoxic pulmonary
vasoconstriction in isolated perfused rabbit lungs. Respir. Physiol. 2000; 123: 109-119.
46. Dempsey JA, Romer L, Rodman J, Miller J, Smith C. Consequences of exercise-induced respiratory
muscle work. Respir. Physiol. Neurobiol. 2006 ; 28;151(2-3): 242-50.
47. De Saussure HB. Journal de l’ascension du Mont blanc. Editions Guérin, Chamonix, 2007.
48. Di Prampero PE, Metabolic and circulatory limitations to VO2 max at the whole animal level. J. Exp.
Biol. 1985; 115: 319-331.
49. Di Prampero PE, Factors limiting maximal performance in humans. Eur. J. Appl. Physiol. 2003; 90:
420-429.
50. Dorrington KL, Clar C, Young JD, Jonas M, Tansley JG, Robbins PA. Time course of the human
pulmonary vascular response to 8 hours of isocapnic hypoxia. Am. J. Physiol. 1997; 273: H1126-1134.
51. Duplain H, Sartori C, Lepori M, Egli M, Allemann Y, Nicod P, Scherrer U. Exhaled nitric oxide in
high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against
inflammation. Am. J. Respir. Crit. Care Med. 2000; 162: 221-224.
52. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, Bonan R, Crepeau J. Reduced
pulmonary clearance of endothelin-1 in pulmonary hypertension. Am. Heart J. 1998; 135: 614-620.
53. Fagan KA, McMurtry I, Radman DM. Nitric oxide synthase in pulmonary hypertension: lessons from
knockout mice. Physiol. Res 2000; 49: 539-48.
54. Faoro V, Huez S, Giltaire S, Pavelescu A, van Osta A, Moraine JJ, Guenard H, Martinot JB, Naeije R.
Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes. J.
Appl. Physiol. 2007; 103(4): 1161-5.
55. Faoro V, Lamotte M, Deboeck G, Pavelescu A, Huez S, Guenard H, Martinot JB, Naeije R. Effects of
sildenafil on exercise capacity in hypoxic normal subjects. High Alt. Med. Biol. 2007; 8: 155-163.
56. Favret F, Richalet JP. Exercise and hypoxia: The role of the autonomic nervous system. Respir. Physiol.
Neurobiol. 2007; 158: 280-286.
57. Ferretti G, di Prampero PE. Factors limiting maximal O2 consumption: effects of acute changes in
ventilation. Respir. Physiol. 1995; 99: 259-71.
58. Ferretti G, Moia C, Thomet JM, Kayser B. The decrease of maximal oxygen consumption during
hypoxia in man: a mirror image of the oxygen equilibrium curve. J. Physiol. Lond. 1997; 498: 231-237.
59. Fischler M, Dorschner L, Debrunner J, Brunner-La Rocca HP, Kliencke S, Birheim A, Bloch K,
Mairbaurl H, Maggiorini M. Maximum exercise capacity at high altitude is not influenced by prophylaxis
with dexamethasone or tadalafil in HAPE-susceptible subjects. Abstract presented at the 14th International
Hypoxia Symposium, Lake Louise, Alberta, Canada, 2005.
60. Fleg JL, Piña IL, Balady GJ, Chaitman BR, Fletcher B, Lavie C, Limacher MC, Stein RA, Williams M,
Bazzarre T. Assessment of functional capacity in clinical and research applications: An advisory from the
Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart
Association. Circulation. 2000; 102(13): 1591-7.
61. Fulco CS, Muza SR, Ditzler D, Lammi E, Lewis SF, Cymerman A. Effect of acetazolamide on leg
endurance exercise at sea level and simulated altitude. Clin. Sci. 2006; 110: 683-692.
62. Fulco CS, Rock PB, Cymerman A. Maximal and submaximal exercise performance at altitude. Aviat.
Space Environ. Med. 1998; 69: 793-801.
63. Fulco CS, Rock PB, Cymerman A. Improving athletic performance: is altitude residence or altitude
training helpful? Aviat. Space Environ. Med. 2000 ; 71: 162-171.
64. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G,
Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil Use in Pulmonary Arterial Hypertension
(SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.
2005; 353: 2148-2157.
65. Garner SH, Sutton JR, Burse RL, McComas AJ, Cymerman A, Houston CS. Operation Everest II:
neuromuscular performance under conditiond of extreme simulated altitude. J. Appl. Physiol. 1990; 68:
1167-1172.
66. Garske LA, Brown MG, and Morrison SC. Acetazolamide reduces exercise capacity and increases leg
fatigue under hypoxic conditions. J. Appl. Physiol. 2003; 94: 991-996.
67. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W,
Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest
Base camp, Ann. Intern. Med. 2004; 141: 169-77.
68. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A,
Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary
hypertension: a randomised controlled trial. Lancet. 2002; 360: 895-900.
69. Goerre S, Wenk M, Bärtsch P, Lüscher TF, Niroomand F, Hohenhaus E, Oelz O, Reinhart WH.
Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation. 1995; 91:
359-364.
70. Grassi B, Marzorati M, Kayser B, Bordini M, Colombini A, Conti M, Marconi C, Cerretelli P. Peak
blood lactate and blood lactate vs workload during acclimatisation to 5050m and in deacclimatization. J
Appl. Physiol. 1996; 80: 685-692.
71. Green HJ, Sutton J, Cymerman A, Yung PM, Houston CS. Operation Everest II: adaptations in human
skeletal muscle. J. Appl. Physiol. 1989; 66: 2454-2461.
72. Green HJ, Sutton J, Yung PM, Cymerman A, Houston CS. Operation Everest II: muscle energy during
maximal exhausive exercise. J. Appl. Physiol. 1989; 66: 142-150.
73. Grocott M, Richardson A, Montgomery H, Mythen M. Caudwell Xtreme Everest: a field study of human
adaptation to hypoxia. Crit. Care. 2007; 11(4): 151.
74. Grover RF, Weil JV, Reeves JT. Cardiovascular adaptation to exercise at high altitude. Exerc. Sport Sci.
Rev. 1986;14:269-302.
75. Groves BM, Droma T, Sutton LR, McCullough RG, McCullough RE, Zhuang J, Rapmund G, Sun S,
Janes C, Moore JG. Minimal hypoxic pulmonary hypertension in normal Tibetans at 3658m. J. Appl.
Physiol. 1993; 74: 312-318.
76. Groves BM, Reeves JT, Sutton JR, Wagner PD, Cymerman A, Malconian MK, Rock PB, Young PM,
Houston CS. Operation Everest II: elevated high-altitude pulmonary resistance unresponsive to oxygen. J.
Appl. Physiol. 1987; 63(2): 521-30.
77. Gründig E, Dehnert C, Mereles D, Koehler R, Olschewski H, Bärtsch P, Janssen B. Enhanced hypoxic
pulmonary vasoconstriction in families of adults or children with idiopathic pulmonary arterial
hypertension. Chest. 2005; 128: 630S-633S.
78. Gründig E, Janssen B, Mereles D, Barth U, Borst MM, Vogt IR, Fischer C, Olschewski H, Kuecherer
HF, Kübler W. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary
pulmonary hypertension gene. Circulation. 2000; 102(10): 1145-50.
79. Gründig E, Mereles D, Hildebrandt W, Swenson ER, Kübler W, Kuecherer H, Bärtsch P. Stress Doppler
echocardiography for identification of susceptibility to high altitude pulmonary edema. J. Am. Coll. Cardiol.
2000; 15, 35(4): 980-7.
80. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The Effects of phosphodiesterase-5
inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory
efficiency, and oxygen uptake kinetics in chronic heart failure. J. Am. Coll. Cardiol. 2004; 44: 2339-48
81. Gujic M, Houssière A, Xhaët O, Argacha JF, Denewet N, Noseda A, Jespers P, Melot C, Naeije R, van
de Borne P. Does endothelin play a role in chemoreception during acute hypoxia in normal men? Chest.
2007; 131(5): 1467-72.
82. Hackett PH, Roach RC. High-altitude illness. N. Engl. J. Med. 2001; 345: 107-14.
83. Hackett PH, Schoene RB, Winslow RM, Peters RM Jr, West JB. Acetazolamide and exercise in
sojourners to 6,300 meters--a preliminary study. Med. Sci. Sports Exerc. 1985; 17: 593-597.
84. Halperin BD, Sun S, Zhuang J, Droma T, Moore LG. ECG observations in Tibetans and Han residents
of Lhasa. J. Electrocardiol. 1998; 31: 237-43.
85. Heath D, Williams D, Rios-Dalenz J, Calderon M, Gosney J. Small pulmonary arterial vessels of
Aymara Indians of the Bolivian Andes. Histopathology. 1990; 16: 565-71.
86. Hepple RT, Hogan MC, Stary C, Bebout DE, Mathieu-Costello O, Wagner PD. Structural basis of
muscle O2 diffusing capacity: evidence from muscle function in situ. J Appl Physiol. 2000; 88(2): 560-6.
87. Hochachka PW, Stanley C, Merkt J, Sumar-Kalinowski J. Metabolic meaning of elevated levels of
oxidative enzymes in high altitude adapted animals: an interpretive hypothesis. Respir. Physiol. 1983; 52(3):
303-13.
88. Höhne C, Krebs MO, Seiferheld M, Boemke W, Kaczmarczyk G, Swenson ER. Acetazolamide prevents
hypoxic pulmonary vasoconstriction in conscious dogs. J. Appl. Physiol. 2004; 97: 515-521.
89. Höhne C, Pickerodt PA, Francis RC, Boemke W, Swenson ER. Pulmonary vasodilation by
acetazolamide during acute hypoxia is not related to carbonic anhydrase inhibition. Am. J. Physiol. Lung
Cell. Mol. Physio. 2007; 292: L178-184.
90. Hopkins SR, Bogaard HJ, Niizeki K, Yamaya Y, Ziegler MG, Wagner PD. Beta-adrenergic or
parasympathetic inhibition, heart rate and cardiac output during normoxic and acute hypoxic exercise in
humans. J. Physiol. 2003; 550: 605-615.
91. Horstman D, Weiskopf R, Jackson RE. Work capacity during 3 week sojourn at 4300m: effects of
relative polycythemia. J. Appl. Physiol. 1980; 49: 311-18.
92. Houston CS, Sutton JR, Cymerman A, Reeves JT. Operation Everest II: man at extreme altitude. J.
Appl. Physiol. 1987: 63; 877-82.
93. Huez S, Faoro V, Vachiery JL, Unger P, Martinot JB, Naeije R. High altitude induced right heart failure.
Circulation. 2007; 115: 108-109.
94. Huez S, Naeije R, Faoro V. Cardiac limitation to exercise capacity at high altitudes. Dans Aldashev A,
Naeije R (eds.) Problems of High Altitude Medicine and Biology, Springer. 2007; pp221-229.
95. Huez S, Retailleau K, Unger P, Pavelescu A, Vachiéry JL, Derumeaux G, Naeije R. Right and left
ventricular adaptation ta hypoxia: a tissue Doppler imaging study. Am. J. Physiol. Heart Circ. Physiol. 2005;
289: H1391-H1398.
96. Imray CH, Myers SD, Pattinson KT, Bradwell AR, Chan CW, Harris S, Collins P, Wright AD. Effect of
exercise on cerebral perfusion in humans at high altitude. J. Appl. Physiol. 2005; 99(2): 699-706.
97. Johnson BD, Babcock MA, Suman OE, Dempsey JA. Exercise-induced diaphragmatic fatigue in healthy
humans. J. Physiol. 1993; 460: 385-405.
98. Jones NL, Sutton JR, Taylor RR, and Toews CJ. Effect of pH on cardiorespiratory and metabolic
responses to exercise. J. Appl. Physiol. 1977; 43: 959–964.
99. Karliner JS, Sarnquist FF, Graber DJ, Peters RM, West JB. The electrocardiogram at extreme altitude:
Experience on Mt. Everest. Am. Heart J. 1985; 109: 505-13.
100. Kayser B. Exercise begins and ends in the brain. Eur. J. Appl. Physiol. 2003; 90: 411-419.
101. Kayser B, Ferretti G, Grassi B, Binzoni T, Cerretelli P. Maximal lactic capacity at altitude : effect of
bicarbonate loading. J. Appl. Physiol. 1993; 3: 1070-1074.
102. Kayser B, Hoppeler H, Claasen H, Cerretelli P. Muscle structure and performance capacity of
Himalayan Sherpas. J. Appl. Physiol. 1991; 70: 1938-42.
103. Kayser B, Narici M, Einzoni T, Grassi B, Cerretelli P. Fatigue and exhaustion in chronic hypobaric
hypoxia : influence of exercising muscle mass. J. Appl. Physiol. 1994; 76: 635-640.
104. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the
inspiratory collapse of the inferior vena cava. Am. J. Cardiol. 1990; 15; 66(4): 493-6.
105. Kitabatake A, Inoue M, Asao M, Masuyama T, Tanouchi J, Morita T, Mishima M, Uematsu M,
Shimazu T, Hori M, Abe H. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler
technique. Circulation. 1983; 68: 302-309.
106. Kojonazarov BK, Imanov BZ, Amatov TA, Mirrakhimov MM, Naeije R, Wilkins MR, Aldashev AA.
Noninvasive and invasive evaluation of pulmonary artery pressure in highlanders. Eur. Respir. J. 2007; 29:
352-356.
107. Koskolou MD, Roach RC, Calbet JA, Radegran G, Saltin B. Cardiovascular response to dynamic
exercise with acute anemia in humans. Am. J. Physiol. Heart Circ. Physiol. 1997; 273: H1787-93.
108. Lenfant C, Sullivan K. Adaptations to high altitude. New England Journal Medicine. 1971; 284(23):
1298-1309.
109. Lundby C, Boushel R, Robach P, Moller K, Saltin B, Calbet JA. During hypoxic exercise some
vasoconstriction is needed to match O
2delivery with O
2demand at the microcirculatory level. J. Physiol.
2007 Oct 11.
110. Lundby C, Calbet JA, van Hall G, Saltin B, Sander M. Pulmonary gas exchange at maximal
exercise in Danish lowlanders during 8 wk of acclimatization to 4100 m and in high-altitude Aymara
natives. Am. J. Physiol. 2004; 287(5): R1202-8.
111. Lundby C, Pilegaard H, Andersen JL, van Hall G, Sander M, Calbet JA. Acclimatization to 4100 m
does not change capillary density or mRNA expression of potential angiogenesis regulatory factors in
human skeletal muscle. J. Exp. Biol. 2004; 207: 3865-71.
112. Lundby C, Sander M, van Hall G, Saltin B, Calbet JA. Maximal exercise and muscle oxygen extraction
in acclimatizing lowlanders and high altitude natives. J. Physiol. 2006: 573.2: 535-547.
113. Lundby C, van Hall G. Peak heart rates at extreme altitudes. High Alt. Med. Biol. 2001; 2: 41-45.
114. McLellan T, Jacobs I, Lewis W. Acute altitude exposure and altered acid–base states II. Effects on
exercise performance and muscle and blood lactate. Eur. J. Appl. Physiol. 1988; 57: 445–451.
115. Maggiorini M, Brunner-La Rocca HP, Peth S, Fischler M, Bohm T, Bernheim A, Kiencke S, Bloch
KE, Dehnert C, Naeije R, Lehmann T, Bärtsch P, Mairbäurl H. Both tadalafil and dexamethasone may
reduce the incidence of high-altitude pulmonary edema: A randomized trial. Ann. Intern. Med. 2006; 145:
497-506.
116. Maggiorini M, Leon-Velarde F. High-altitude pulmonary hypertension ; a pathophysiological entity to
different diseases. Eur. Respir. J. 2003; 22: 1019-25.
117. Maggiorini M, Mélot C, Pierre S, Pfeiffer F, Greve I, Sartori C, Lepori M, Hauser M, Scherrer U,
Naeije R. High altitude pulmonary edema is initially caused by an increased capillary pressure. Circulation.
2001; 103: 2078-2083.
118. Mairbaurl H, Oelz O, Bartsch P. Interactions between Hb, Mg, DPG, ATP and Cl determine the change
in Hb-O2 affinity at high altitude. J. Appl. Physiol. 1993; 74: 40-48.
119. McGuire BJ, Secomb TW. Theoretical predictions of maximal oxygen consumption in hypoxia: effects
of transport limitations. Respir. Physiol. Neurobiol. 2004; 143(1): 87-97.
120. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for
pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001; 104:
2797-2802.
121. Messner R: L’Everest sans oxygène. Arthaud, Paris. 1979; pp 152.
122. Milledge JS. Electrocardiographic changes at high altitude. Brit. Heart J. 1962; 25: 291-298.
123. Modesti PA, Vanni S, Morabito M, Modesti A, Marchetta M, Gamberi T, Sofi F, Savia G, Mancia G,
Gensini GF, et coll. Role of endothelin-1 in exposure to high altitude: Acute mountain sickness and
endothelin-1 (acme-1) study. Circulation. 2006; 114: 1410-1416.
124. Mollard P, Woorons X, Letournel M, Lamberto C, Favret F, Pichon A, Baudry M, Richalet JP.
Determinants of maximal oxygen uptake in moderate acute hypoxia in endurance athletes. Eur. J. of Appl.
Physiol. 2007; 100(6): 663-673.
125. Moore LG, Niermeyer S, Zamudio S. Human adaptation to high altitude: regional and life-cycle
perspectives. Am. J. Phys. Antropol. 1998; 27: 25-64
126. Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J. Appl. Physiol. 2005;
98: 390-403.
127. Naeije R. Pulmonary vascular function. In: Pulmonary Circulation. Diseases and their Treatment.
Edited by AJ Peacock and LJ Rubin. Arnold, London. 2004; chap 1, pp 3-13.
128. Naeije R. Pulmonary vascular resistance: a meaningless variable? Intens. Care Med. 2003; 29:
526-529.
129. Naeije R, Torbicki A. More on the noninvasive diagnosis pulmonary hypertension. Doppler
echocardiography revisited. Eur. Respir. J. 1995; 8: 1445-1449.
130. Noakes TD, Calbet JA, Boushel R, Søndergaard H, Rådegran G, Wagner PD, Saltin B. Central
regulation of skeletal muscle recruitment explains the reduced maximal cardiac output during exercise in
hypoxia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004; 287: R996-999.
131. Noakes TD, St Clair Gibson A. Logical limitation to the “catastrophe” models of fatigue during
exercise in human. J. Sports Med. 2004; 38: 648-649.
132. Noakes TD, Peltonen JE, Rusko HK. Evidence that a central governor regulates exercise performance
during acute hypoxia and hyperoxia. J. Exp. Biol. 2001; 204: 3225-34.
133. Orizio C, Esposito F, Veicsteinas A. Effect of acclimatization to high altitude (5050m) on motor unit
activation pattern and muscle performance. J. Appl. Physiol. 1994; 77: 2840-2844.
134. Paintal AS. Some recent advances in studies on J-receptors. Adv. Exp. Med. Biol. 1995; 381: 15-25.
135. Peltonen JE, Tikkanen HO, Rusko HK. Cardiorespiratory responses to exercise in acute hypoxia,
hyperoxia and normoxia. Eur. J. Appl. Physiol. 2001; 85(1-2): 82-8.
136. Penaloza D, Arias-Stella J. The heart and pulmonary circulation in high altitude: Healthy highlanders
and chronic moutain sickness. Circulation. 2007; 115: 1132-1146.
137. Piiper J, Scheid P. Comparison of diffusion and perfusion limitations in alveolar gas exchange. Respir
Physiol. 1983; 51: 287-290.
138. Pugh LGCE, Gill MB, Lahiri S, Milledge JS, Ward MP, West JB. Muscular exercise at great altitudes.
J. Appl. Physiol. 1964; 19: 431-440.
139. Pugh LGCE. Cardiac output in muscular exercise at 5800m. J. Appl. Physiol. 1964; 19: 441-447.
140. Pugh LG. Physiological and medical aspects of the Himalayan scientific and mountaineering
expedition, 1960-61. Br. Med. J. 1962; 8: 2(5305): 621-7.
141. Reeves JT, Grover RF. Insights by Peruvian scientists into pathogenesis of chronic hypoxic pulmonary
Dans le document
CHAPITRE I : Introduction générale
(Page 71-83)